Mavodelpar
Mavodelpar (REN001) is a selective PPARδ agonist. Mavodelpar suppresses glomerular injury and renal fibrosis. Mavodelpar can be used for the research of primary mitochondrial myopathies (PMM) and long-chain fatty acid oxidation disorders (LC-FAOD) [1]. Mavodelpar is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
Product Specifications
CAS Number
[1604815-32-8]
Product Name Alternative
REN001; HPP593
UNSPSC
12352005
Target
PPAR
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor
Applications
COVID-19-anti-virus
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/mavodelpar.html
Purity
99.89
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(O[Na])COC1=CC=C(OC/C=C(C2=CC=C(F)C=C2)\C3=CC=C(C#CCN4CCOCC4)C=C3)C=C1C
Molecular Formula
C31H29FNNaO5
Molecular Weight
537.55
References & Citations
[1]Omachi K, et al. PPARδ agonism ameliorates renal fibrosis in an Alport syndrome mouse model. Kidney360. 2022 Nov 29.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
